Saranas has announced the appointment of Philippe Généreux as its chief medical officer. Généreux is the co-director of the Structural Heart Disease Program at Morristown Medical Center, Morristown, USA. Saranas’ lead product is its Early Bird bleed detection system, which – press release reports – is moving through final product testing. FDA submission is expected later this year.
The Early Bird device is a standard vascular access sheath embedded with sensors that is designed to detect bleeding from a blood vessel accidentally injured during endovascular procedures such as transcatheter aortic valve implantation, large bore haemodynamic support device placement, or other complex cardiac interventions, where the femoral artery or vein is used to gain access to the heart. The technology was invented at the Texas Heart Institute.
“I am very excited and pleased to be part of the Saranas team and to support the development of a solution designed to protect and, in some cases, save the lives of patients undergoing endovascular procedures by allowing early detection and better management of bleeding complications occurring during or after those procedures. I have also been impressed with the team’s focus on innovation and look forward to shaping and executing Saranas’ strategy to advance the clinical utility of the Early Bird system,” comments Généreux.
Saranas president and chief executive officer Zaffer Syed says: “We are pleased to welcome Dr Généreux to the Saranas team during this pivotal moment in the company’s history. Dr Généreux will play an important leadership role in helping to bring the benefits of our Early Bird Detection System to patients who potentially may benefit from this new technology as soon as possible. His entrepreneurial spirit paired with his clinical research and medical training as an interventional cardiologist make him an invaluable asset as we work to bring the Early Bird to market.”
Généreux will also play a leadership role with the Saranas Scientific Advisory Board (SAB) which now includes the following members:
- Amir Kaki, medical director of the Cardiac Catheterization Laboratory, Detroit Medical Center Heart Hospital (USA)
- Dimitrios Karmpaliotis, director of Chronic Total Occlusions, Complex and High Risk Angioplasty, Columbia University Medical Center (USA)
- James McCabe, medical director, Cardiac Catheterization Labs, University of Washington (USA)
During his career, Généreux has been an interventional cardiologist at the Columbia Medical Center, NYC and at the Hôpital du Sacré-Coeur de Montréal, Canada. He also served as the director of the Angiographic Core Laboratory at the Cardiovascular Research Foundation in New York (USA).